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Abstract:  
Purpose:  
To report on a 10-year assessment following the application of rhBMP-7 
for reconstruction of alveolar cleft.  
Method:  
This study was conducted as prospective phase II clinical trial on 9 
unilateral and two bilateral alveolar clefts which received rhBMP-7 
(Osigraft).  The mean age of patients at surgery was 10.4 years. Six 
months postoperatively, occlusal radiographs were taken to evaluate bone 
formation at the cleft site. Patients were followed up within the routine 
cleft care pathway for up to 10 years to monitor the impact of BMP-7 on 
orthodontic treatments and maxillary growth. Radiographs were taken 
according to the standard cleft care protocol.  
Results:  
The radiographic assessment of the UCLP cases suggested good bone 
formation with a Kindelan score at grade 1 or 2. The bilateral alveolar 
cleft cases had a score of grade 3 or 4 indicating failure or partial 
failure.  The children with successful grafts underwent a routine 
orthodontics follow-up without incident. The maxillary growth appeared 
similar to that of cases grafted with autogenous bone. No long term 
complications or abnormal pattern of bone formation were detected. 
Conclusions:  
The study provides unique evidence on the long term safety of rhBMP-7 
when applied at the area of skeletal immaturity for the reconstruction of 
alveolar clefts in children. 
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Abstract: 
Purpose:  
To report on a 10-year assessment following the application of rhBMP-7 for 
reconstruction of alveolar cleft.  
Method:  
This study was conducted as prospective phase II clinical trial on 9 unilateral and two 
bilateral alveolar clefts which received rhBMP-7 (Osigraft).  The mean age of patients 
at surgery was 10.4 years. Six months postoperatively, occlusal radiographs were 
taken to evaluate bone formation at the cleft site. Patients were followed up within the 
routine cleft care pathway for up to 10 years to monitor the impact of BMP-7 on 
orthodontic treatments and maxillary growth. Radiographs were taken according to 
the standard cleft care protocol.  
Results:  
The radiographic assessment of the UCLP cases suggested good bone formation with 
a Kindelan score at grade 1 or 2. The bilateral alveolar cleft cases had a score of grade 
3 or 4 indicating failure or partial failure.  The children with successful grafts 
underwent a routine orthodontics follow-up without incident. The maxillary growth 
appeared similar to that of cases grafted with autogenous bone. No long term 
complications or abnormal pattern of bone formation were detected. 
Conclusions:  
The study provides unique evidence on the long term safety of rhBMP-7 when 
applied at the area of skeletal immaturity for the reconstruction of alveolar clefts in 
children. 
 
 
 
 
 
 
 
 
 
 
Introduction:  
Autogenous bone graft is the gold standard for the reconstruction of alveolar cleft 
which is associated with cleft lip and palate.
1  
However, harvesting of bone graft is 
associated with well documented morbidities including pain, scarring, alteration in 
sensation and swelling.
2
 Researchers worldwide are interested in discovering 
alternative treatment modalities, based on the recent advances in tissue 
bioengineering, to avoid these morbidities. The use of the osteoinductive growth 
factors including bone morphogenetic proteins (BMPs) has been considered for the 
reconstruction of the alveolar clefts. BMPs stimulate osteogenesis for the healing of 
skeletal fractures, the osteoinductive abilities of BMP-2 and BMP-7 are well 
documented.
3,4
  
Bone morphogenetic protein 2 (BMP-2) has been used for the reconstruction of 
alveolar cleft defects over the last 10 years.
5-7
 The quality and quantity of bone 
formation in alveolar cleft is dependent on the dose of the cytokines that is locally 
applied at the cleft site. BMP-2 at a low dose of 50Ug ml
-1
 failed to induce bone 
formation, whereas, up to 59% of the surgical defect was reconstructed with new bone 
formation when the concentration of BMP-2 was raised to 250ug ml
-1
. However, this 
was associated with severe postoperative gingival swelling during the first week 
following surgery.
8
 The development of a localized swelling following the application 
of BMP-2 is well documented.
9-11
 
Comparative analysis between BMP-2 with autologous bone harvested from the iliac 
crest for the reconstruction of alveolar clefts has been carried out. The doses of the 
BMP-2 ranged from 1.05–1.5 mg ml−1 which was delivered by type I collagen 
sponge.  In all the studies BMP-2 was successful in inducing bone formation 
comparable to the cases which received autogenous bone grafts.
5,7,8
 
There is a concern of using BMP in the pediatric population and the possibility of induction 
of malignancy.  The Food and Drug Administration has licensed the clinical 
application of recombinant BMP-7 (rhBMP-7) for the non-union of long bone 
fractures and spinal fusion.
12
 The clinical applications of BMP-7 in the maxillofacial 
region are limited, but it has been utilized in some studies following the elevation of 
the maxillary sinus membrane for augmentation of the floor.
13
 
We have conducted a series of pre-clinical studies on the application of BMP-7 for 
reconstruction of the jaw bones which have showed successful bone regeneration at 
the created surgical defects and minimal postoperative complications.
14-17
 
Following these, we have conducted a clinical trial on the application of BMP-7 for 
the reconstruction of alveolar cleft which showed, radiographically, a satisfactory 
bone formation in the majority of cases with a successful eruption of the cleft canine 
through the site of reconstruction.
18
 Similar to the preclinical studies, postoperative 
complications were minimal. 
One of the major concerns regarding the application of cytokines including BMPs in 
growing children has always been their long-term impact on maxillary growth and the 
potential for enduring complications which include ectopic bone formation in the 
surrounding tissue and the ankylosis of the adjacent teeth. Most of the reported 
clinical manifestations and complications following the application of BMP in 
alveolar clefts are limited to the first year following surgery.  Herford et al.,
5
 reviewed 
the patients after 4 months, whereas Dickinson et al.,
7
 and Alonso et al.,
8
 reviewed the 
patients after 1 year.  We could not find reports, in the English literature, on the long 
term effects of BMPs following the application in the maxillofacial region during 
skeletal immaturity of the childhood period.  
 
Aim of the study: 
The aim of this study is to provide the first 10-year postoperative assessment 
following the application of rhBMP-7 (Op1) for the reconstruction of alveolar cleft   
 
Methods:  
This study was reviewed and approved by West Glasgow Ethics Committee  
(EudraCT number: 2005-004392-38, REC reference number 05/S0703/1), the 
Medicines and Healthcare Products Regulatory Authority (MHRA) 
(CTA:27410/0001/001-0001, protocol number R050187), and the Research & 
Development (R&D Reference:R050187). This study was conducted as a prospective 
phase II clinical trial on 11 healthy cases, 9 unilateral and two bilateral alveolar 
clefts.
18
 The mean age of patients at operation was 10.4 years ranging from 8.8 years 
to 11.6 years. In all the cases the alveolar cleft was reconstructed with rhBMP-7 
(Osigraft, OP1, Stryker Biotech, UK).  This was reviewed and approved by the local 
ethics committee, regulatory authority (MHRA) and research & development.  For 
each case a vial of Osigraft® had 3.5mg of eptotermin alfa (a recombinant human 
osteogenic protein 1”Op-1”) in bovine collagen (a bioresorbable scaffold) was applied 
at the alveolar defect. As explained in our previous publication,
18
 The alveolar cleft 
was exposed following a standard surgical technique, the nasal mucosa was dissected, 
reflected upward and sutured before the application of the graft (Figure 1 a).. A putty 
additive (Stryker Biotech) containing carboxymethyl cellulose was added to the 
Osigraft® and this mixture was reconstituted with 2 to 3 ml of sterile 9 mg/ml sodium 
chloride solution (0.9% w/v) prior to use. The graft was then packed locally into the 
cleft region. The reconstituted product was administered by direct surgical placement 
in the alveolar cleft site in contact with the bone surfaces (Figure 1b).  Periosteal 
release was carried out to allow the stretch and the suturing of the mucoperiosteal flap 
without tension. Standard postoperative care was provided and patients were 
discharged from the hospital the day after surgery. 
 
Patients were examined clinically every three days of the first 10 days and then on a 
weekly basis for three months, followed by another evaluation at 6 months and one 
year following surgery. The patients were reviewed on annual basis up to 10 years. 
The following clinical assessments were carried put: 
1. Immediately following surgery the magnitude of facial swelling, discomfort 
and any signs of infection following surgery.  Immediate post-operative 
radiographs were taken to assess the shape and appearance of the grafts and 
the position of the associated impacted. At three months the healing pattern 
and eruption of the adjacent teeth was assessed. Six months following surgery, 
the patients underwent a radiographic examination which was used for the 
initial assessment 
2. The facial growth, residual facial asymmetries or abnormal growth, alteration 
in sensation, deformities related to the naso-maxillary complex, and the 
overall pattern of the jaw bones were assessed at each review appointment. 
3. Assessment of the site of the graft and reporting in the healing process, bone 
over growth, exposure, dehiscence, or fistula formation Buccaly or palatally. 
4. Eruption of the adjacent teeth the impacted canine at the graft site. 
5. Assessment of the medio-lateral maxillo-mandibular  occlusal relationship and 
recording of any cross bites 
6. 3. Assessment of the vertical occlusal relationship and recording of any lateral 
open bites. 
7. At each appointment the growth of the maxilla was evaluated. 
 
In summary, patients were followed up within the routine care pathway for 10 years 
to monitor the impact of BMP-7 on the course of the orthodontic treatment, long term 
complications and the pattern of maxillary growth. Routine radiographs were taken 
according to the standard cleft care Scotland audit protocol for patients’ management. 
 
Results:  
Surgical: 
Clinically, the surgical site healed well, immediate postoperative swelling was similar 
to that of a routine dento-alveolar procedure. Patients were discharged from the 
hospital the following day after surgery. No critical incidents were reported. We have 
previously evaluated bone regeneration in the unilateral alveolar cleft using the 
Kindelan Scoring system as grade 1 (>75% in fill) in all the cases except one which 
scored grade II (50-70% bone infill). The trabeculation of the newly formed tissue 
was similar to the surrounding bone. None of these cases required further grafting. 
Both patients with bilateral clefts,  at routine radiographic follow up,  showed 
minimal bony infill (Figure 2) on at least one side and subsequently underwent further 
conventional grafting procedures. The results of the subsequent bone graft were 
successful. The Kindelan score, which was used for grading bone formation, 
suggested a successful outcome grade 1 or 2 (Figures 3b, 3c) for the children with 
UCLP.  The details of these early findings have been published.
18
 
 
Orthodontics  
In all the UCLP cases, except one, the cleft canine erupted through the graft 
spontaneously.  The children subsequently commenced orthodontic care aged 
between 9 yrs and 14 years. The duration of the subsequent orthodontic treatment 
ranged from 8 to 20 months.  In the majority of the children the space was closed 
between the cleft canine and cleft central incisor.  
 Facial growth & long term complications 
In the surgically managed UCLP cases the maxillary growth appeared similar to that 
of cases grafted with autogenous bone. A detailed radiograpahic analysis was not 
conducted in this study. Lateral radiographs are only taken where it is considered 
appropriate to aid the clinical orthodontic diagnosis.  The analysed records when 
taken before puberty (Figures 4) and post puberty (Figure 5s) showed values 
consistent with those for a routine cleft population with unilateral or bilateral cleft lip 
and palate.  Figure 6 shows the soft tissue analysis, and figure 7 shows the  evaluation 
of the skeletal pattern of one of the UCLP cases.   
 
We did not detect excessive bone fusion or excessive bony growth at the site where 
BMP was applied.  None of the patient showed what would be considered an 
abnormal growth pattern for this cohort of patients. The symmetry of the face was 
monitored throughout the course of orthodontic treatment. None of the UCLP cases 
appeared to develop asymmetry secondary to the application of BMP-7 that would be 
considered different from those who receive conventional grafting procedures. 
Reviewing the patients’ medical records did not reveal systemic or skeletal 
abnormalities that were of relevance to the application of BMP.  The placement of the 
rhBMP- 7 into direct contact with the adjacent tissue did not cause ectopic bone 
formation or damage to the adjacent teeth. 
 
Discussion:  
In this study bone regeneration at the grafted sites was evaluated using Kindelan score 
which is widely used for the evaluation of alveolar bone grafts. It is a four point 
radiographic scale that assesses bone formation at the alveolar cleft independent to the 
eruption of the canine. Bilateral cleft lip and palate cases had a score of grade 3 or 4 
for the grafted sites which is an indicative of graft failure. In both children the cleft 
canines failed to erupt through the graft site. The eruption of the cleft related canine in 
the UCLP cases occurred spontaneously in the bioengineered bone in all cases except 
one, which would be considered, despite the small numbers, a comparable level of 
spontaneous eruption of other studies using more conventional graft materials.
2019-,21
 
The duration of orthodontic treatment (8-20months) would be considered standard for 
children with cleft lip and palate and comparable with other cleft related studies.
 19
 
In the case of failed eruption, pre-operative radiographs suggest the cleft canine was 
in an unfavourable (horizontal) position pre-surgery and therefore unlikely to erupt 
through the graft site.  Although this may have contributed to the failure, a recent 
study found that canine angulation prior to the graft appears to have no impact of its 
ability to erupt spontaneously.
22
 
The age (9-14yrs) and duration (8-20months) of orthodontic treatment would be 
considered standard for children with cleft lip and palate and comparable with other 
cleft related studies.
 19
 
 
 
In the majority of the children the orthodontic plan was for space closure anteriorly 
between the cleft canine and cleft central incisor. The clinical decision as to whether 
to open or close the space orthodontically in the two cases that subsequently 
underwent space opening was based on the malocclusion rather than a lack of bone 
available for tooth movement on post-operative radiographs. However, that quality of 
bone graft analysed by radiographs six months post-graft appears to be only weakly 
correlated with whether space closure is possible long-term.
23
  
 
In our experience the cohort showed a growth pattern similar (Figure 7) to those 
where autogenous bone graft has been used for the reconstruction of the alveolar 
defect.  Direct comparison between the two groups (conventional bone graft versus 
BMP) was not considered part of this study as the sample size is too small for a robust 
evaluation. We do note however that orthodontic camouflage to mask the skeletal 
discrepancy was achievable in most of the cases which confirms a relatively mild 
nature of the skeletal discrepancy.  
 
 The successful manufacture of the recombinant BMP allowed its commercial 
production. 
27
 
24
 This facilitated a wide range of clinical studies to promote bone 
healing in spinal fusions and the management of the non-union of long bones.  
BMP has the ability to induce the differentiation of mesenchymal stem cells to 
osteobalsts and also promote the proliferation of the commented cells toward the 
osteogenic lineage for bone regeneration.
 25
 However, the long term impact of the 
application of BMP for alveolar cleft reconstruction on the orthodontic tooth 
movements and bone growth is sparse in English literature.
26
 
In this study,  the morbidity associated with a donor site was eliminated by using 
rhMBP_7 for the reconstruction of the alveolar cleft.  The intensity of the surgical 
procedure was reduced which facilitated postoperative recovery.  The duration of the 
stay in hospital was one day which is shorter than that is in some surgical units, when 
iliac crest bone graft is harvested. Radiographic assessment gave an objective and 
reliable, although two dimensional indication of the quality and quantity of newly 
formed bone. These patients were treated prior to the routine use of CBCT for the 
evaluation of the volume of alveolar cleft and bone formation. In bilateral alveolar 
cleft cases, bone formation was limited, the premaxilla was not mobile but 
radiographs confirmed the failure of bone formation. We believe the main reason for 
the unsuccessful treatment of the bilateral alveolar clefts is the e small volume of the 
injected material. Increasing the dose of the applied BMP was not an option due to the 
hypothetical potential risk of excessive bone formation.  
There is debate in the literature regarding the application of BMP in early years of life 
and a considerable concern regarding the implantation site,  mainly in areas of skeletal 
immaturity.
27
 The findings of our study appear to confirm the safety of applying 
BMP-7 at immature skeletal sites. The clinical evaluation of the patients  and the 
assessment of the lateral cephalographs whenever they were taken at various follow 
up intervals did not reveal adverse or unexpected effects that are not routinely seen in 
conventional iliac crest bone graft cases. 
There is strong evidence in the literature suggesting that BMPs do not only affect 
bone, but are expressed in several tissues.
27
 BMP-2 and -7 are expressed in prostate 
cancer,
28
 breast cancer,
29
 osteosarcomas,
30
 and odontogenic tumors.
31
There is 
evidence that BMPs may play a role in the development and progression of malignant 
tumors, but the exact mechanism is not clear. The long term safety of the clinical 
application of BMPs for the bony reconstruction of alveolar cleft has not yet been 
fully investigated.  In this study, the presented data provide some assurance as none of 
the cases which received BMP-7 developed tumors related to the maxillofacial region 
and we did not detect ectopic bone formation or ankylosis of the adjacent teeth.  
Despite the satisfactory results in this study, one of the major obstacles of the routine 
application of BMP for the reconstruction of the alveolar cleft is its high cost which 
has to be counter balanced with the morbidities associated with the harvesting of iliac 
crest bone graft.  Health authorities and policy makers should work closely with the 
industry to reduce the cost of the manufacturer of the rhBMP to facilitate its global 
utilisation. Another alternative to reduce the cost of the application of recombinant 
cytokines is their combination with osseoconductive materials. The outcomes of 15 
patients grafted with autogenous bone were compared with 15 patients grafted with a 
combination of BMP-2 and Demineralised Bone Matrix (DBM). Occlusal radiographs 
and cone beam CTs were taken three months after surgery and evaluated using 
Bergland, Chelsea, Long and Yen scales. The results showed equivalent successful 
outcomes.
32
 
We are not aware of studies which directly compare between BMP2 and BMP7 for 
the reconstruction of the alveolar cleft, this worse considering in the future.  
None of the patients in this study received dental implants. The cleft site was either 
closed orthodontically or the impacted canines, having erupted at the grafted site. 
Therefore, there was no opportunity to carry out histological assessment to evaluate 
the quality or the architectural characteristics of the regenerated bone. 
The use of a collagen carrier in the presented cases allowed rhBMP-7 to be easily 
applied and directly injected at the alveolar cleft site. This facilitated access to the 
surgical site and is advantageous because it requires minimal exposure of the cleft 
which reduces the morbidity of the surgical procedure.   
One of the objectives of the reconstruction of the alveolar cleft is the simultaneous 
augmentation of the bony foundation of the alar base to correct the associated nasal 
asymmetry, which is readily achievable with a mono-cortical block of cortico-
cancelleous autogenous bone graft.
33
 This cannot be achieved with the injectable 
rhBMP-7 due to its putty consistency. This could  be accomplished  in the future with 
the development of a block of biological scaffolding that is loaded with rhBMP or 
seeded with stem cells to induce bone formation. The collagen carrier used in this 
study is not ideal to achieve this particular objective. 
 
This study suffers from the small sample size and the absence of the direct 
comparison with the UCLP cases which has autogenous bone graft for the 
reconstruction of the alveolar cleft.  This requires further investigation.  
Conclusions: 
This 10 year follow up provides assurance regarding the safety of BMP-7 when 
applied at the area of skeletal immaturity. Patients did not develop clinical or 
radiographic manifestations of bony abnormalities. There appeared to be no additional 
alteration in growth pattern or development of tumours with the application of BMP-7 
in children.  Residual facial asymmetry was consistent with that of conventional iliac 
crest bone graft cases. Orthodontic movement of the teeth through the grafts site 
progressed in a similar manner to conventional cases. The high rate of success in this 
study with UCLP cases may encourage a larger scale clinical trial and facilitate phase 
III comparative studies in comparison with autogenous bone graft.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legends of the figures: 
 
Figures 1a: 
 Exposure of the right alveolar cleft  
Figure 1b 
The injection of rhBMP-7  in the alveolar cleft  
Alveolar cleft, the clinical application of BMP-7 at the cleft site 
 
Figure 2: 
 Ppostoperative  occlusal radiograph showing failure of bone formation in one of the 
bilateral alveolar cleft cases 
 
Figure 3 a: 
Preoperative frontal view showing the characteristic features of UCLP on the left side.  
 
Figure 3b: 
Immediate preoperative occlusal radiogarph  showing the alveolar cleft  
 
 Figure 3c: 
Occlusal radiograph 6 months following the application of rhBMP-7 at the alveolar 
cleft, showing bone formation and the partial eruption of the impacted canine. 
 
Figures 3d: 
Postoperative palatal view of the UCLP cases showing good soft tissue healing and 
the eruption of the impacted canine  6 months after the application of rhBMP-7 at the 
left alveolar cleft. 
 
 Preoperative photographs and radiographs 
Frontal view, anterior occlusal radiographs before &  6 months following the 
application of rhBMP-7 at the alveolar cleft h showing bone formation at the cleft 
site, intraoral photograph showing the eruption of the canine at the grafted cleft, . 
 
Figure 3e: 
Lateral cephalograph at 6 month following the reconstruction of alveolar cleft using 
rhBMP-7. 
  
Figures 4 a: 
Frontal, profile and three-quarter facial  photographs of the same patient at five years 
following the grafting of the alveolar cleft and before complete cessation of the 
growth  
 
 
Figures 4b.  
Intra-oral photographs : fFive years years following alveolar cleft reconstruction with 
rhBMP-7 showing good healing, full eruption of the impacted canine and a 
satisfactory growth of the maxilla postoperative views before complete cessation of 
growth   
 
Figures 5a:  
10 years postoperative facial views of the same patient showing a mild degree of 
maxillary hypoplasia, normal labial seal, and asymmetry of the left nostril.  
Frontal view,  left profile view, lateral cephalograph , submento-vertex view, dental  
occlusion. 
 
Figures 5b: 
10 years postoperative view of the dental arches showing mild cross bite at the left 
maxillary incisors, full eruption of the canine on the left cleft side, normal appearance 
& contour of the buccal mucosa of the grafted side and absence of overgrowth or 
clinical pathological findings.  
 
Figure 5c: 
10 years lateral cephalograph showing a satisfactory maxillary growth relative to the 
UCLP of the same case which was grafted with rhBMP-7 
  
 
Figure 6: A: Soft tissue analysis to evaluate the antero-posterior growth of the maxilla   
The TVL is constructed from the natural head position through subnasale.  
Soft tissue A (stA) and soft tissue B (stB) points are projected to the TVL.  
 
Figure 7: Skeletal and dental analysis of the lateral cephaolograph of one of the 
surgically managed UCLP cases.  
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Abstract: 
Purpose:  
To report on a 10-year assessment following the application of rhBMP-7 for 
reconstruction of alveolar cleft.  
Method:  
This study was conducted as prospective phase II clinical trial on 9 unilateral and two 
bilateral alveolar clefts which received rhBMP-7 (Osigraft).  The mean age of patients 
at surgery was 10.4 years. Six months postoperatively, occlusal radiographs were 
taken to evaluate bone formation at the cleft site. Patients were followed up within the 
routine cleft care pathway for up to 10 years to monitor the impact of BMP-7 on 
orthodontic treatments and maxillary growth. Radiographs were taken according to 
the standard cleft care protocol.  
Results:  
The radiographic assessment of the UCLP cases suggested good bone formation with 
a Kindelan score at grade 1 or 2. The bilateral alveolar cleft cases had a score of grade 
3 or 4 indicating failure or partial failure.  The children with successful grafts 
underwent a routine orthodontics follow-up without incident. The maxillary growth 
appeared similar to that of cases grafted with autogenous bone. No long term 
complications or abnormal pattern of bone formation were detected. 
Conclusions:  
The study provides unique evidence on the long term safety of rhBMP-7 when 
applied at the area of skeletal immaturity for the reconstruction of alveolar clefts in 
children. 
 
 
 
 
 
 
 
 
 
 
Introduction:  
Autogenous bone graft is the gold standard for the reconstruction of alveolar cleft 
which is associated with cleft lip and palate.
1  
However, harvesting of bone graft is 
associated with well documented morbidities including pain, scarring, alteration in 
sensation and swelling.
2
 Researchers worldwide are interested in discovering 
alternative treatment modalities, based on the recent advances in tissue 
bioengineering, to avoid these morbidities. The use of the osteoinductive growth 
factors including bone morphogenetic proteins (BMPs) has been considered for the 
reconstruction of the alveolar clefts. BMPs stimulate osteogenesis for the healing of 
skeletal fractures, the osteoinductive abilities of BMP-2 and BMP-7 are well 
documented.
3,4
  
Bone morphogenetic protein 2 (BMP-2) has been used for the reconstruction of 
alveolar cleft defects over the last 10 years.
5-7
 The quality and quantity of bone 
formation in alveolar cleft is dependent on the dose of the cytokines that is locally 
applied at the cleft site. BMP-2 at a low dose of 50Ug ml
-1
 failed to induce bone 
formation, whereas, up to 59% of the surgical defect was reconstructed with new bone 
formation when the concentration of BMP-2 was raised to 250ug ml
-1
. However, this 
was associated with severe postoperative gingival swelling during the first week 
following surgery.
8
 The development of a localized swelling following the application 
of BMP-2 is well documented.
9-11
 
Comparative analysis between BMP-2 with autologous bone harvested from the iliac 
crest for the reconstruction of alveolar clefts has been carried out. The doses of the 
BMP-2 ranged from 1.05–1.5 mg ml−1 which was delivered by type I collagen 
sponge.  In all the studies BMP-2 was successful in inducing bone formation 
comparable to the cases which received autogenous bone grafts.
5,7,8
 
There is a concern of using BMP in the pediatric population and the possibility of induction 
of malignancy.  The Food and Drug Administration has licensed the clinical 
application of recombinant BMP-7 (rhBMP-7) for the non-union of long bone 
fractures and spinal fusion.
12
 The clinical applications of BMP-7 in the maxillofacial 
region are limited, but it has been utilized in some studies following the elevation of 
the maxillary sinus membrane for augmentation of the floor.
13
 
We have conducted a series of pre-clinical studies on the application of BMP-7 for 
reconstruction of the jaw bones which have showed successful bone regeneration at 
the created surgical defects and minimal postoperative complications.
14-17
 
Following these, we have conducted a clinical trial on the application of BMP-7 for 
the reconstruction of alveolar cleft which showed, radiographically, a satisfactory 
bone formation in the majority of cases with a successful eruption of the cleft canine 
through the site of reconstruction.
18
 Similar to the preclinical studies, postoperative 
complications were minimal. 
One of the major concerns regarding the application of cytokines including BMPs in 
growing children has always been their long-term impact on maxillary growth and the 
potential for enduring complications which include ectopic bone formation in the 
surrounding tissue and the ankylosis of the adjacent teeth. Most of the reported 
clinical manifestations and complications following the application of BMP in 
alveolar clefts are limited to the first year following surgery.  Herford et al.,
5
 reviewed 
the patients after 4 months, whereas Dickinson et al.,
7
 and Alonso et al.,
8
 reviewed the 
patients after 1 year.  We could not find reports, in the English literature, on the long 
term effects of BMPs following the application in the maxillofacial region during 
skeletal immaturity of the childhood period.  
 
Aim of the study: 
The aim of this study is to provide the first 10-year postoperative assessment 
following the application of rhBMP-7 (Op1) for the reconstruction of alveolar cleft   
 
Methods:  
This study was reviewed and approved by West Glasgow Ethics Committee  
(EudraCT number: 2005-004392-38, REC reference number 05/S0703/1), the 
Medicines and Healthcare Products Regulatory Authority (MHRA) 
(CTA:27410/0001/001-0001, protocol number R050187), and the Research & 
Development (R&D Reference:R050187). This study was conducted as a prospective 
phase II clinical trial on 11 healthy cases, 9 unilateral and two bilateral alveolar 
clefts.
18
 The mean age of patients at operation was 10.4 years ranging from 8.8 years 
to 11.6 years. In all the cases the alveolar cleft was reconstructed with rhBMP-7 
(Osigraft, OP1, Stryker Biotech, UK).  This was reviewed and approved by the local 
ethics committee, regulatory authority (MHRA) and research & development.  For 
each case a vial of Osigraft® had 3.5mg of eptotermin alfa (a recombinant human 
osteogenic protein 1”Op-1”) in bovine collagen (a bioresorbable scaffold) was applied 
at the alveolar defect. As explained in our previous publication,
18
 The alveolar cleft 
was exposed following a standard surgical technique, the nasal mucosa was dissected, 
reflected upward and sutured before the application of the graft (Figure 1 a). A putty 
additive (Stryker Biotech) containing carboxymethyl cellulose was added to the 
Osigraft® and this mixture was reconstituted with 2 to 3 ml of sterile 9 mg/ml sodium 
chloride solution (0.9% w/v) prior to use. The graft was then packed locally into the 
cleft region. The reconstituted product was administered by direct surgical placement 
in the alveolar cleft site in contact with the bone surfaces (Figure 1b).  Periosteal 
release was carried out to allow the stretch and the suturing of the mucoperiosteal flap 
without tension. Standard postoperative care was provided and patients were 
discharged from the hospital the day after surgery. 
 
Patients were examined clinically every three days of the first 10 days and then on a 
weekly basis for three months, followed by another evaluation at 6 months and one 
year following surgery. The patients were reviewed on annual basis up to 10 years. 
The following clinical assessments were carried put: 
1. Immediately following surgery the magnitude of facial swelling, discomfort 
and any signs of infection following surgery.  Immediate post-operative 
radiographs were taken to assess the shape and appearance of the grafts and 
the position of the associated impacted. At three months the healing pattern 
and eruption of the adjacent teeth was assessed. Six months following surgery, 
the patients underwent a radiographic examination which was used for the 
initial assessment 
2. The facial growth, residual facial asymmetries or abnormal growth, alteration 
in sensation, deformities related to the naso-maxillary complex, and the 
overall pattern of the jaw bones were assessed at each review appointment. 
3. Assessment of the site of the graft and reporting in the healing process, bone 
over growth, exposure, dehiscence, or fistula formation Buccaly or palatally. 
4. Eruption of the adjacent teeth the impacted canine at the graft site. 
5. Assessment of the medio-lateral maxillo-mandibular  occlusal relationship and 
recording of any cross bites 
6. 3. Assessment of the vertical occlusal relationship and recording of any lateral 
open bites. 
7. At each appointment the growth of the maxilla was evaluated. 
 
In summary, patients were followed up within the routine care pathway for 10 years 
to monitor the impact of BMP-7 on the course of the orthodontic treatment, long term 
complications and the pattern of maxillary growth. Routine radiographs were taken 
according to the standard cleft care Scotland audit protocol for patients’ management. 
 
Results:  
Surgical: 
Clinically, the surgical site healed well, immediate postoperative swelling was similar 
to that of a routine dento-alveolar procedure. Patients were discharged from the 
hospital the following day after surgery. No critical incidents were reported. We have 
previously evaluated bone regeneration in the unilateral alveolar cleft using the 
Kindelan Scoring system as grade 1 (>75% in fill) in all the cases except one which 
scored grade II (50-70% bone infill). The trabeculation of the newly formed tissue 
was similar to the surrounding bone. None of these cases required further grafting. 
Both patients with bilateral clefts,  at routine radiographic follow up,  showed 
minimal bony infill (Figure 2) on at least one side and subsequently underwent further 
conventional grafting procedures. The results of the subsequent bone graft were 
successful. The Kindelan score, which was used for grading bone formation, 
suggested a successful outcome grade 1 or 2 (Figures 3b, 3c) for the children with 
UCLP.  The details of these early findings have been published.
18
 
 
Orthodontics  
In all the UCLP cases, except one, the cleft canine erupted through the graft 
spontaneously.  The children subsequently commenced orthodontic care aged 
between 9 yrs and 14 years. The duration of the subsequent orthodontic treatment 
ranged from 8 to 20 months.  In the majority of the children the space was closed 
between the cleft canine and cleft central incisor.  
 Facial growth & long term complications 
In the surgically managed UCLP cases the maxillary growth appeared similar to that 
of cases grafted with autogenous bone. A detailed radiograpahic analysis was not 
conducted in this study. Lateral radiographs are only taken where it is considered 
appropriate to aid the clinical orthodontic diagnosis.  The analysed records when 
taken before puberty (Figures 4) and post puberty (Figure 5s) showed values 
consistent with those for a routine cleft population with unilateral or bilateral cleft lip 
and palate.  Figure 6 shows the soft tissue analysis, and figure 7 shows the  evaluation 
of the skeletal pattern of one of the UCLP cases.   
 
We did not detect excessive bone fusion or excessive bony growth at the site where 
BMP was applied.  None of the patient showed what would be considered an 
abnormal growth pattern for this cohort of patients. The symmetry of the face was 
monitored throughout the course of orthodontic treatment. None of the UCLP cases 
appeared to develop asymmetry secondary to the application of BMP-7 that would be 
considered different from those who receive conventional grafting procedures. 
Reviewing the patients’ medical records did not reveal systemic or skeletal 
abnormalities that were of relevance to the application of BMP.  The placement of the 
rhBMP- 7 into direct contact with the adjacent tissue did not cause ectopic bone 
formation or damage to the adjacent teeth. 
 
Discussion:  
In this study bone regeneration at the grafted sites was evaluated using Kindelan score 
which is widely used for the evaluation of alveolar bone grafts. It is a four point 
radiographic scale that assesses bone formation at the alveolar cleft independent to the 
eruption of the canine. Bilateral cleft lip and palate cases had a score of grade 3 or 4 
for the grafted sites which is an indicative of graft failure. In both children the cleft 
canines failed to erupt through the graft site. The eruption of the cleft related canine in 
the UCLP cases occurred spontaneously in the bioengineered bone in all cases except 
one, which would be considered, despite the small numbers, a comparable level of 
spontaneous eruption of other studies using more conventional graft materials.
19-,21
 
The duration of orthodontic treatment (8-20months) would be considered standard for 
children with cleft lip and palate and comparable with other cleft related studies.
 19
 
In the case of failed eruption, pre-operative radiographs suggest the cleft canine was 
in an unfavourable (horizontal) position pre-surgery and therefore unlikely to erupt 
through the graft site.  Although this may have contributed to the failure, a recent 
study found that canine angulation prior to the graft appears to have no impact of its 
ability to erupt spontaneously.
22
 
 
 
In the majority of the children the orthodontic plan was for space closure anteriorly 
between the cleft canine and cleft central incisor. The clinical decision as to whether 
to open or close the space orthodontically in the two cases that subsequently 
underwent space opening was based on the malocclusion rather than a lack of bone 
available for tooth movement on post-operative radiographs. However, that quality of 
bone graft analysed by radiographs six months post-graft appears to be only weakly 
correlated with whether space closure is possible long-term.
23
  
 
In our experience the cohort showed a growth pattern similar (Figure 7) to those 
where autogenous bone graft has been used for the reconstruction of the alveolar 
defect.  Direct comparison between the two groups (conventional bone graft versus 
BMP) was not considered part of this study as the sample size is too small for a robust 
evaluation. We do note however that orthodontic camouflage to mask the skeletal 
discrepancy was achievable in most of the cases which confirms a relatively mild 
nature of the skeletal discrepancy.  
 
 
The successful manufacture of the recombinant BMP allowed its commercial 
production. 
24
 This facilitated a wide range of clinical studies to promote bone healing 
in spinal fusions and the management of the non-union of long bones.  
BMP has the ability to induce the differentiation of mesenchymal stem cells to 
osteobalsts and also promote the proliferation of the commented cells toward the 
osteogenic lineage for bone regeneration.
 25
 However, the long term impact of the 
application of BMP for alveolar cleft reconstruction on the orthodontic tooth 
movements and bone growth is sparse in English literature.
26
 
In this study,  the morbidity associated with a donor site was eliminated by using 
rhMBP_7 for the reconstruction of the alveolar cleft.  The intensity of the surgical 
procedure was reduced which facilitated postoperative recovery.  The duration of the 
stay in hospital was one day which is shorter than that is in some surgical units, when 
iliac crest bone graft is harvested. Radiographic assessment gave an objective and 
reliable, although two dimensional indication of the quality and quantity of newly 
formed bone. These patients were treated prior to the routine use of CBCT for the 
evaluation of the volume of alveolar cleft and bone formation. In bilateral alveolar 
cleft cases, bone formation was limited, the premaxilla was not mobile but 
radiographs confirmed the failure of bone formation. We believe the main reason for 
the unsuccessful treatment of the bilateral alveolar clefts is the e small volume of the 
injected material. Increasing the dose of the applied BMP was not an option due to the 
hypothetical potential risk of excessive bone formation.  
There is debate in the literature regarding the application of BMP in early years of life 
and a considerable concern regarding the implantation site,  mainly in areas of skeletal 
immaturity.
27
 The findings of our study appear to confirm the safety of applying 
BMP-7 at immature skeletal sites. The clinical evaluation of the patients  and the 
assessment of the lateral cephalographs whenever they were taken at various follow 
up intervals did not reveal adverse or unexpected effects that are not routinely seen in 
conventional iliac crest bone graft cases. 
There is strong evidence in the literature suggesting that BMPs do not only affect 
bone, but are expressed in several tissues.
27
 BMP-2 and -7 are expressed in prostate 
cancer,
28
 breast cancer,
29
 osteosarcomas,
30
 and odontogenic tumors.
31
There is 
evidence that BMPs may play a role in the development and progression of malignant 
tumors, but the exact mechanism is not clear. The long term safety of the clinical 
application of BMPs for the bony reconstruction of alveolar cleft has not yet been 
fully investigated.  In this study, the presented data provide some assurance as none of 
the cases which received BMP-7 developed tumors related to the maxillofacial region 
and we did not detect ectopic bone formation or ankylosis of the adjacent teeth.  
Despite the satisfactory results in this study, one of the major obstacles of the routine 
application of BMP for the reconstruction of the alveolar cleft is its high cost which 
has to be counter balanced with the morbidities associated with the harvesting of iliac 
crest bone graft.  Health authorities and policy makers should work closely with the 
industry to reduce the cost of the manufacturer of the rhBMP to facilitate its global 
utilisation. Another alternative to reduce the cost of the application of recombinant 
cytokines is their combination with osseoconductive materials. The outcomes of 15 
patients grafted with autogenous bone were compared with 15 patients grafted with a 
combination of BMP-2 and Demineralised Bone Matrix (DBM). Occlusal radiographs 
and cone beam CTs were taken three months after surgery and evaluated using 
Bergland, Chelsea, Long and Yen scales. The results showed equivalent successful 
outcomes.
32
 
We are not aware of studies which directly compare between BMP2 and BMP7 for 
the reconstruction of the alveolar cleft, this worse considering in the future.  
None of the patients in this study received dental implants. The cleft site was either 
closed orthodontically or the impacted canines, having erupted at the grafted site. 
Therefore, there was no opportunity to carry out histological assessment to evaluate 
the quality or the architectural characteristics of the regenerated bone. 
The use of a collagen carrier in the presented cases allowed rhBMP-7 to be easily 
applied and directly injected at the alveolar cleft site. This facilitated access to the 
surgical site and is advantageous because it requires minimal exposure of the cleft 
which reduces the morbidity of the surgical procedure.   
One of the objectives of the reconstruction of the alveolar cleft is the simultaneous 
augmentation of the bony foundation of the alar base to correct the associated nasal 
asymmetry, which is readily achievable with a mono-cortical block of cortico-
cancelleous autogenous bone graft.
33
 This cannot be achieved with the injectable 
rhBMP-7 due to its putty consistency. This could  be accomplished  in the future with 
the development of a block of biological scaffolding that is loaded with rhBMP or 
seeded with stem cells to induce bone formation. The collagen carrier used in this 
study is not ideal to achieve this particular objective. 
 
This study suffers from the small sample size and the absence of the direct 
comparison with the UCLP cases which has autogenous bone graft for the 
reconstruction of the alveolar cleft.  This requires further investigation.  
Conclusions: 
This 10 year follow up provides assurance regarding the safety of BMP-7 when 
applied at the area of skeletal immaturity. Patients did not develop clinical or 
radiographic manifestations of bony abnormalities. There appeared to be no additional 
alteration in growth pattern or development of tumours with the application of BMP-7 
in children.  Residual facial asymmetry was consistent with that of conventional iliac 
crest bone graft cases. Orthodontic movement of the teeth through the grafts site 
progressed in a similar manner to conventional cases. The high rate of success in this 
study with UCLP cases may encourage a larger scale clinical trial and facilitate phase 
III comparative studies in comparison with autogenous bone graft.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legends of the figures: 
 
Figure 1a: 
 Exposure of the right alveolar cleft  
Figure 1b 
The injection of rhBMP-7  in the alveolar cleft  
 
Figure 2: 
 Postoperative  occlusal radiograph showing failure of bone formation in one of the 
bilateral alveolar cleft cases 
 
Figure 3 a: 
Preoperative frontal view showing the characteristic features of UCLP on the left side.  
 
Figure 3b: 
Immediate preoperative occlusal radiogarph  showing the alveolar cleft  
 
 Figure 3c: 
Occlusal radiograph 6 months following the application of rhBMP-7 at the alveolar 
cleft, showing bone formation and the partial eruption of the impacted canine. 
 
Figures 3d: 
Postoperative palatal view of the UCLP cases showing good soft tissue healing and 
the eruption of the impacted canine  6 months after the application of rhBMP-7 at the 
left alveolar cleft. 
 
. 
 
Figure 3e: 
Lateral cephalograph at 6 month following the reconstruction of alveolar cleft using 
rhBMP-7. 
  
Figures 4 a: 
Frontal, profile and three-quarter facial  photographs of the same patient at five years 
following the grafting of the alveolar cleft and before complete cessation of the 
growth  
 
 
Figures 4b.  
Intra-oral photographs  five years following alveolar cleft reconstruction with rhBMP-
7 showing good healing, full eruption of the impacted canine and a satisfactory 
growth of the maxilla    
 
Figures 5a:  
10 years postoperative facial views of the same patient showing a mild degree of 
maxillary hypoplasia, normal labial seal, and asymmetry of the left nostril.  
 
Figures 5b: 
10 years postoperative view of the dental arches showing mild cross bite at the left 
maxillary incisors, full eruption of the canine on the left cleft side, normal appearance 
& contour of the buccal mucosa of the grafted side and absence of overgrowth or 
clinical pathological findings.  
 Figure 5c: 
10 years lateral cephalograph showing a satisfactory maxillary growth relative to the 
UCLP of the same case which was grafted with rhBMP-7 
  
 
Figure 6: A: Soft tissue analysis to evaluate the antero-posterior growth of the maxilla   
The TVL is constructed from the natural head position through subnasale.  
Soft tissue A (stA) and soft tissue B (stB) points are projected to the TVL.  
 
Figure 7: Skeletal and dental analysis of the lateral cephaolograph of one of the 
surgically managed UCLP cases.  
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